Floatz logo

Enobosarm

Her2-Receptor Negative Breast Cancer

City of Hope Medical CenterSmall moleculePhase 2Dormant
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
41/ 100
Competitive Position
89/ 100

Competitive context

186 Active assets in the Her2-Receptor Negative Breast Cancer cohort.

Asset / SponsorPhaseRating
Palbociclib
Helwan University
Phase 2BBB
Exemestane
National Cancer Institute (NCI)
Phase 4BBB
Pembrolizumab
UNC Lineberger Comprehensive Cancer Center
Phase 2BBB
Atezolizumab
TransThera Sciences (Nanjing), Inc.
Phase 2BB
Docetaxel
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 2/3BB

View all 50 →

Same molecule, other indications

Enobosarm is also rated in:

muscular atrophyDormant
B
Indicative · Phase 3
63 / 100
View asset →
estrogen-receptor negative breast cancerDormant
B
Indicative · Phase 2
56 / 100
View asset →
breast cancerActive
B
Indicative · Phase 3
56 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →